# BIOMEDICAN, Inc.

> BIOMEDICAN is a Fremont, California synthetic-biology company building a B2B fermentation platform around engineered Yarrowia lipolytica, an oil-producing yeast. Its pitch is to manufacture rare cannabinoids and other high-value molecules with consistent purity, shorter production cycles and lower resource use than crop extraction. The company has named CBG/CBGA, CBN/CBNA, THCA, THCV/THCVA and astaxanthin as targets, while public patent records confirm two U.S. grants covering cannabinoid production in yeast. Commercial scale, current revenue and named customers remain undisclosed.

- **Founded:** 2017
- **Headquarters:** Fremont, United States
- **Founders:** Maxim (Max) Mikheev (Founder, CEO and Chief Science Officer)
- **Team size:** Approximately 13 employees in the supplied company data; LinkedIn lists 11-50 employees.
- **Products:** CBG/CBGA, THCV/THCVA, CBN/CBNA, THCA, Astaxanthin
- **Notable:** Founded in Fremont in 2017 around Maxim Mikheev's genomics and strain-engineering experience., Announced successful biosynthesis of CBG/CBGA and plans for large-scale production in 2020., Expanded the platform to astaxanthin in under six months, according to a 2020 company announcement.

## Products & services

- **CBG/CBGA** — Rare cannabinoid and precursor produced with engineered Yarrowia yeast; BIOMEDICAN announced successful biosynthesis and plans for large-scale production in 2020.
- **THCV/THCVA** — Rare cannabinoid pair listed in the company's fermentation portfolio for pharmaceutical, food, beverage and wellness ingredient applications.
- **CBN/CBNA** — Rare cannabinoid pair listed as a target of the company's yeast biosynthesis platform.
- **THCA** — A non-intoxicating cannabinoid acid listed among BIOMEDICAN's target compounds.
- **Astaxanthin** — A fermentation-derived carotenoid developed as proof that the platform could extend beyond cannabinoids; a separate SciFeed venture was planned for commercialization.
- **Biosynthesis platform** — Organism engineering, fermentation and process know-how for producing high-value, bioidentical molecules with proprietary oily yeast.

## Achievements

- Founded in Fremont in 2017 around Maxim Mikheev's genomics and strain-engineering experience.
- Announced successful biosynthesis of CBG/CBGA and plans for large-scale production in 2020.
- Expanded the platform to astaxanthin in under six months, according to a 2020 company announcement.
- Received U.S. Patent No. 11,149,291 for production of cannabinoids in yeast in October 2021.
- Received a continuation patent, U.S. Patent No. 11,939,613, in March 2024.
- Maintained the first U.S. patent with a four-year maintenance-fee payment recorded in April 2025.

## Latest updates

- **2025-04** — A four-year small-entity maintenance-fee payment was recorded for U.S. Patent No. 11,149,291.
- **2024-03** — U.S. Patent No. 11,939,613, a continuation covering production of cannabinoids in yeast, was granted to BIOMEDICAN.
- **2021-10** — BIOMEDICAN's first U.S. cannabinoid-production patent, No. 11,149,291, was issued.
- **2021-01** — The company said it planned to spin astaxanthin commercialization into a separate venture called SciFeed because the buyer base did not overlap with rare cannabinoids.

## Links

- Website: https://biomedican.com
- LinkedIn: https://www.linkedin.com/company/biomedican
- Twitter/X: https://twitter.com/biomedican
- YouTube: https://www.youtube.com/channel/UC-inVw2b0FBO6PFLCNy-zUg
- Facebook: https://www.facebook.com/biomedicaninc

---

Profile page: https://yespress.io/biomedican-inc
Published by YesPress — https://yespress.io
Last updated: 2026-08-21